U.S. Markets closed

SHAREHOLDER ALERT: Pawar Law Group Announces a Securities Class Action Lawsuit Against Tetraphase Pharmaceuticals, Inc. - TTPH

NEW YORK, NY / ACCESSWIRE / September 21, 2018 / Pawar Law Group announces that a class action lawsuit has been filed on behalf of shareholders who purchased shares of Tetraphase Pharmaceuticals, Inc. (TTPH) pursuant and/or traceable to Tetraphase's allegedly false and/or misleading registration statement and prospectus issued in connection with its July 2017 secondary public offering (''SPO'' or the ''Offering''); and/or from March 8, 2017 through February 13, 2018, both dates inclusive (the ''Class Period''). The lawsuit seeks to recover damages for Tetraphase investors under the federal securities laws.

If you're interested in joining the Tetraphase class action, go to http://pawarlawgroup.com/cases/tetraphase-pharmaceuticals-inc/ or call Vik Pawar, Esq. toll-free at 888-589-9804 or email vik@pawarlawgroup.com for information on the class action.

NO CLASS HAS YET BEEN CERTIFIED IN THE ABOVE ACTION. UNTIL A CLASS IS CERTIFIED, YOU ARE NOT REPRESENTED BY COUNSEL UNLESS YOU RETAIN ONE. YOU MAY RETAIN COUNSEL OF YOUR CHOICE. YOU MAY ALSO REMAIN AN ABSENT CLASS MEMBER AND DO NOTHING AT THIS POINT. AN INVESTOR'S ABILITY TO SHARE IN ANY POTENTIAL FUTURE RECOVERY IS NOT DEPENDENT UPON SERVING AS LEAD PLAINTIFF.

According to the lawsuit, defendants during the Class Period made materially false and/or misleading statements and/or failed to disclose that: (1) Tetraphase was increasing the patient enrollment in its IGNITE3 trial from 1,000 patients to 1,200 patients to meet the trial's primary endpoints (within the 10% non-inferiority margin); (2) the enrollment of more patients in the trial indicated that the existing population was inadequate to meet the trial's primary endpoints; and (3) that, as a result of the foregoing, defendants' statements about Tetraphase's business, operations, and prospects, were materially false and/or misleading and/or lacked a reasonable basis. When the true details entered the market, the lawsuit claims that investors suffered damages.

A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than September 25, 2018. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. If you wish to join the litigation, go to http://pawarlawgroup.com/cases/tetraphase-pharmaceuticals-inc/ to join the class action. You may also contact Vik Pawar of Pawar Law Group toll free at 888-589-9804 or via email at vik@pawarlawgroup.com.

Pawar Law Group represents investors from around the world.

Vik Pawar, Esq.
Pawar Law Group P.C
20 Vesey Street Suite 1210
New York, NY 10007
Tel: (917) 261-2277
Toll Free: 888-589-9804
Fax: (212) -571-0938
vik@pawarlawgroup.com
www.pawarlawgroup.com

SOURCE: Pawar Law Group

https://www.accesswire.com/512373/SHAREHOLDER-ALERT-Pawar-Law-Group-Announces-a-Securities-Class-Action-Lawsuit-Against-Tetraphase-Pharmaceuticals-Inc-TTPH